# US 6,727,242 B2 · Pharmacological treatment for sleep apnea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,242 B2
- Document ID: US6727242B2
- Status: Granted
- Kind: B2
- Application number: 10/016,901
- Filed: 2001-12-14
- Published: 2002-07-04
- Granted: 2004-04-27
- Earliest claimed: 1998-02-27
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Miodrag Radulovacki; David W. Carley
- Web page: https://patentgrep.com/patent/US6727242B2

## CPC

- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/16: Central respiratory analeptics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.

## Claims

### Claim 1

A method of ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of ondansetron.

### Claim 2 (depends on 1)

The method of claim 1 wherein the sleep-related breathing disorder is selected from the group consisting of obstructive sleep apnea syndrome, apnea of prematurity, congenital central hypoventilation syndrome, obesity hypoventilation syndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

### Claim 3

A method of ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of a composition comprising ondansetron and a serotonin receptor agonist.

### Claim 4 (depends on 3)

The method of claim 3 wherein the sleep-related breathing disorder is selected from the group consisting of obstructive sleep apnea syndrome, apnea of prematurity, congenital central hypoventilation syndrome, obesity hypoventilation syndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

### Claim 5 (depends on 3)

The method of claim 3 wherein the serotonin receptor agonist is selected from the group consisting of 8-OH-DPAT, sumatriptan, L694247, buspirone, alnitidan, zalospirone, ipsapirone, gepirone, zolmitriptan, risatriptan, 311C90, α-Me-5-HT, BW723C86, and MCPP.

### Claim 6 (depends on 3)

The method of claim 3 wherein the serotonin receptor agonist is a 5-hydroxytryptamine1 receptor subtype agonist.

### Claim 7 (depends on 3)

The method of claim 3 wherein the serotonin receptor agonist is a 5-hydroxytryptamine2 receptor subtype agonist.

### Claim 8 (depends on 3)

The method of claim 3 wherein the effects of the serotonin receptor agonist are exerted in the central nervous system.

### Claim 9 (depends on 3)

The method of claim 3 wherein the effects of ondansetron are exerted in the peripheral nervous system.

### Claim 10 (depends on 3)

The method of claim 3 wherein the effects of the serotonin receptor agonist are exerted in the central nervous system and wherein the effects of ondansetron are exerted in the peripheral nervous system.

### Claim 11

A method of ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of a serotonin receptor antagonist and an effective amount of a selective serotonin reuptake inhibitor.

### Claim 12 (depends on 11)

The method of claim 11 wherein the sleep-related breathing disorder is selected from the group consisting of obstructive sleep apnea, apnea of prematurity, congenital central hypoventilation syndrome, obesity hypoventilation syndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

### Claim 13 (depends on 11)

The method of claim 11 wherein the serotonin receptor antagonist is selected from the group consisting of ketanserin, cinanserin, LY-53,857j, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557j, 3-tropanyl-indole-3-carboxylate, 3-tropanyl-indole-3-carboxylate methiodide, methysergide, risperidone, cyproheptadine, clozapine, mianserin, ritanserin, granisetron, and ondansetron.

### Claim 14 (depends on 11)

The method of claim 11 wherein the selective serotonin reuptake inhibitor is selected from the group consisting of fluoxetine and paroxetine.
